Total Funding
93
94
Total FundingGrant raised
Growth Score
4 pts
Heat Score
37 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
14313
Preclinical biotech with deep expertise in functional genomics to map genetic variants and advance a rare disease pipeline led by CB-001.
- Nicholas Schafer: Co-Founder & CEO
- Daniel Goldman: Co-Founder & CSO
About the Company
Constantiam Biosciences is a preclinical biotech company with a novel precision genomics platform intended to accelerate rare disease drug discovery and clinical variant interpretation. The company offers curated functional evidence resources, multiplexed functional genetic platforms, and preclinical therapeutic programs, enabling researchers,
clinicians, biopharma companies, and healthcare organizations to improve diagnostic accuracy, patient stratification, and therapeutic development for genetically defined diseases.
